Author: OurCrowd

[Hub Security in PR Newswire] HUB Security shareholders approve $1.28B Nasdaq SPAC merger

Oct 31, 2022 |

TEL AVIV, Israel, Oct. 31, 2022 /PRNewswire/ — HUB Cyber Security (Israel) Limited (TASE: HUB), a developer of Confidential Computing cybersecurity solutions and services (“HUB” or the “Company”), announced today that on October 27, 2022, at the extraordinary general meeting called pursuant to Section 350 of the Companies Law, 1999, its shareholders and optionholders voted to approve the previously announced SPAC merger with Mount Rainier Acquisition Corp (RNER) and delisting from the Tel Aviv Stock Exchange (TASE). Read more...

Read More

[Connected Energy in LABM] How can industry decarbonise old buildings, while struggling with energy costs?

Oct 31, 2022 |

As the manufacturing industry struggles with rising energy costs and pressure to decarbonise, an energy solution, which couldn’t come at a better time for businesses, has been successfully installed at AMRC North West in Lancashire. Two battery energy storage systems (BESS) supplied by Connected Energy have been successfully integrated on the site to link to a range of renewable technologies. Read more...

Read More

[Biolojic in Business Wire] Aulos Bioscience announces FDA clearance of IND Application for AU-007, a novel immunotherapy for the treatment of solid tumors

Oct 31, 2022 |

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AU-007, a monoclonal antibody computationally designed by Biolojic Design. AU-007 leverages a unique approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors. This is the first time that a computationally designed human monoclonal antibody has been cleared for human trials in the United States. Read...

Read More

[Sequentify in PR Newswire] Sequentify collaborates with Yeda, the commercial arm of the Weizmann Institute, under an NIH grant for evaluating the effect of clonal hematopoiesis on cognitive impairment and kidney function decline

Oct 31, 2022 |

REHOVOT, Israel, Oct. 31, 2022 /PRNewswire/ — Sequentify announced its collaboration with Yeda, the commercial arm of the Weizmann Institute of Science (WIS) and NIH, as part of a grant to sequence over 6,000 patients using the Sequentify Myeloid NGS panel, offering cost-effective, high throughput NGS sequencing at scale. Read more...

Read More